arrow
A

Alessandra Romano

University of Catania
H指数:40
被引数:8,258

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infection prevention and management in patients with multiple myeloma treated with bispecific antibodies: a case-based approach for routine clinical practice

多发性骨髓瘤患者接受双特异性抗体治疗时的感染预防与管理:基于病例的方法用于常规临床实践

2026-09-100
OAAI
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus

优化三药类暴露复发/难治性多发性骨髓瘤患者中BCMA靶向T细胞结合疗法的实际应用:一项意大利改良德尔菲共识

Cancers
IF4.4
2026-08-110
OA
Antibacterial and cytotoxic effects of chlorhexidine combined with sodium DNA on oral microorganisms: an in vitro study using Dictyostelium discoideum

氯己定与DNA钠联合对口腔微生物的抗菌和细胞毒性作用:一项使用Dictyostelium discoideum的体外研究

2025-12-310
PRE
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025-12-010
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis
2025-01-140
OAAI
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia

达沙替尼和Selinexor联合治疗慢性粒细胞白血病增强的抗肿瘤活性

2024-07-051
OAAI
Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjects
2024-06-271
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI